Safety Issues Concerning the Medical Use of Cannabis and Cannabinoids

Ware, Mark A.; Tawfik, Vivianne L.

doi:10.1155/2005/312357

Cited by 27 publications

(23 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preparation protocol for APIs extraction sometimes included a preheating step, to enhance the yield of decarboxylation of acid‐APIs (THCA, CBDA): this optional step, and the lack of a standardized temperature and time, greatly contributes to a possibly clinically relevant interlot variability in APIs concentrations (Figure ), as well as to the variability in THCA/THC/CBN or CBDA/CBD ratios …”

Section: Discussionmentioning

confidence: 99%

Cannabinoids concentration variability in cannabis olive oil galenic preparations†

Carcieri

Tomasello

Simiele

et al. 2017

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

Objectives Knowledge of the exact concentration of active compounds in galenic preparations is crucial to be able to ensure their quality and to properly administer the prescribed dose. Currently, the need for titration of extracts is still debated. Considering this, together with the absence of a standard preparation method, the aim of this study was to evaluate cannabinoids concentrations variability in galenic olive oil extracts, to evaluate the interlot and interlaboratory variability in the extraction yield and in the preparation composition. , Bedroliteâ (5 g/50 ml), these were THC 82%, THC 53% and CBD 91%, THC 58% and CBD 59%, respectively. The median extraction yields were greater than 75% for all preparations.Conclusions Our results highlighted a wide variability in THC and CBD concentrations that justify the need for titration and opens further questions about other pharmaceutical preparations without regulatory indication for this procedure.

show abstract

Section: Discussionmentioning

confidence: 99%

Cannabinoids concentration variability in cannabis olive oil galenic preparations†

Carcieri

Tomasello

Simiele

et al. 2017

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

show abstract

“…31 One laboratory study showed that the euphoric effects of single doses of intravenously (0.25 mg) and orally (2 mg) administered nabilone were less pronounced than for $ 9 -THC (17.5 mg oral and 2.2 mg intravenous). 33 Similarly, another laboratory study showed that smoked cannabis (1.83% $ 9 -THC), but not 2 mg oral nabilone, increased elation factor scores on the Profile of Mood States.…”

Section: Discussionmentioning

confidence: 99%

Substitution Profile of the Cannabinoid Agonist Nabilone in Human Subjects Discriminating Δ9-Tetrahydrocannabinol

Lile

Kelly²,

Hays³

2010

Clinical Neuropharmacology

View full text Add to dashboard Cite

These data demonstrate that the interoceptive effects of nabilone are similar to Δ-THC in cannabis users. The overlap in their behavioral effects is likely due to their shared mechanism as CB1 receptor agonists. Given the relative success of agonist replacement therapy to manage opioid, tobacco, and stimulant dependence, these results also support the evaluation of nabilone as a potential medication for cannabis-use disorders.

show abstract

“…Cannabinoids should generally be considered as a third line of treatment. A recent symposium of articles published in this Journal provide further information regarding the use of cannabinoids in pain (259,(270)(271)(272)(273)(274)(275)(276).…”

Section: Cannabinoids Cannabinoids Available By Prescriptionmentioning

confidence: 99%

The Pharmacotherapy of Chronic Pain: A Review

Lynch

Watson

2006

Pain Research and Management

100

View full text Add to dashboard Cite

The past two decades have contributed a large body of preclinical work that has assisted in our understanding of the underlying pathophysiological mechanisms that cause chronic pain. In this context, it has been recognized that effective treatment of pain is a priority and that treatment often involves the use of one or a combination of agents with analgesic action. The current review presents an evidence-based approach to the pharmacotherapy of chronic pain. Medline searches were done for all agents used as conventional treatment in chronic pain. Published papers up to June 2005 were included. The search strategy included randomized, controlled trials, and where available, systematic reviews and meta-analyses. Further references were found in reference sections of papers located using the above search strategy. Agents for which there were no controlled trials supporting efficacy in treatment of chronic pain were not included in the present review, except in cases where preclinical science was compelling, or where initial human work has been positive and where it was thought the reader would be interested in the scientific evidence to date.Key Words: Anticonvulsants; Antidepressants; Cannabinoids; Chronic pain; Opioids; Pharmacotherapy; Topical analgesics La pharmacothérapie de la douleur chronique : Une analyse Les deux dernières décennies ont contribué à un vaste ensemble de travaux précliniques qui nous ont permis de mieux comprendre les mécanismes physiopathologiques sous-jacents responsables de la douleur chronique. Dans ce contexte, il est admis que le traitement efficace de la douleur est une priorité et qu'il exige souvent le recours à un agent ou à une association d'agents ayant une action analgésique. La présente analyse présente une démarche probante de la pharmacothérapie de la douleur chronique. Des recherches dans Medline ont été effectuées sur tous les agents utilisés pour le traitement classique de la douleur chronique. Les articles publiés jusqu'en juin 2005 ont été inclus. La stratégie de recherche incluait les essais aléatoires et contrôlés et, si elles étaient disponibles, les analyses systématiques et les méta-analyses. D'autres références ont été obtenues dans la partie des références des articles trouvés à l'aide de la stratégie de recherche précédente. Les agents dont aucun essai contrôlé n'étayait l'efficacité pour le traitement de la douleur chronique étaient exclus de la présente analyse, sauf si les données scientifiques précliniques étaient convaincantes, si les travaux humains initiaux étaient positifs ou si on pensait que les données scientifiques colligées jusque-là étaient intéressantes pour le lecteur.

show abstract

Safety Issues Concerning the Medical Use of Cannabis and Cannabinoids

Cited by 27 publications

References 108 publications

Cannabinoids concentration variability in cannabis olive oil galenic preparations†

Cannabinoids concentration variability in cannabis olive oil galenic preparations†

Substitution Profile of the Cannabinoid Agonist Nabilone in Human Subjects Discriminating Δ9-Tetrahydrocannabinol

The Pharmacotherapy of Chronic Pain: A Review

Contact Info

Product

Resources

About